Stereotactic Body Radiotherapy for the Treatment of Oligometastatic Renal Cell Carcinoma

• DOI: 10.1097/coc.0b013e31825d52b2
• Publication Date: 2012-12-13T08:15:53Z
• Authors: Mark C. Ranck; Daniel W. Golden; Kimberly S. Corbin; Michael D. Hasselle; Stanley L. Liauw; Walter M. Stadler; Olwen M. Hahn; Ralph R. Weichsel...; Joseph Kamel Salama
• Keywords: Adult; Aged, 80 and over; Male; Kaplan-Meier Estimate; Middle Aged; Radiosurgery; Kidney Neoplasms; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Humans; Female; Dose Fractionation, Radiation; Carcinoma, Renal Cell; Fatigue; Aged; Follow-Up Studies; Retrospective Studies

Objectives: Renal cell carcinoma (RCC) is considered radioresistant, but stereotactic radiosurgery can control intracranial metastases. Advances in radiotherapy, such as body radiotherapy (SBRT), allow high-dose radiation delivery to extracranial sites. Herein, we report our experience treating oligometastatic RCC with SBRT. Methods: Patients and limited metastases were treated on a 3-fraction dose-escalation protocol (8 14 Gy/fraction) or off 10 fractions (4 5 Gy/fraction). Disease was evaluated serial imaging, the Kaplan-Meier method used estimate lesion (LeC), distant control, survival. Results: Eighteen consecutively patients 39 using SBRT; 12 underwent treatment for all metastatic Median follow-up 16.2 months. Treatment well tolerated; most common acute toxicity fatigue (61.1%) late limited. At 2 years, LeC 91.4% overall survival 85%. Those who sites had 2-year of 100% 35.7%. A shorter interval from diagnosis SBRT predicted progression. Freedom any post-SBRT therapy 64.2% at 1 year. Conclusions: In RCC, produces promising minimal toxicity. Further study should be expanded beyond that managing disease. Its selected use may delay requirement systemic therapies.